Last updated: May 26, 2026
Suppliers for SYMDEKO (copackaged tezacaftor/ivacaftor): Which companies make the active ingredients, finished drug product, and copack components?
Executive summary: SYMDEKO (tezacaftor/ivacaftor) copackaged supply chain depends on the specific marketed unit (tablets) and the commercial packaging configuration. The drug is manufactured and supplied through a Novartis-led global system, with external manufacturing and/or component sourcing varying by site, dosage strength, and market. A supplier list can only be produced from verifiable public records (FDA labeling “Manufactured for,” Orange Book manufacturing sites, CMC-exposed registrations, or documented third-party manufacturing/packaging partners). No such supplier-level record set is provided in the prompt, so a complete and accurate supplier roster cannot be stated.
Why can’t a definitive supplier list be provided for SYMDEKO (copackaged)?
- Orange Book dependency: Supplier identification typically relies on Orange Book “Applicant/Holder” plus manufacturer/manufacturing sites tied to listed NDA products.
- Copack configuration dependency: “Copackaged” implies separate carton or kit formats. Supplier attribution can differ between:
- active pharmaceutical ingredient (API) procurement,
- finished dosage manufacturing (tablets),
- packaging and kit assembly (copack/dual bottle systems),
- labeling/secondary packaging runs.
- Market dependency: Certain sites are used for specific countries and release lots, meaning a single universal supplier statement can be wrong.
Result: Without cited, record-backed manufacturing/packaging partner data, any supplier naming would be incomplete or potentially incorrect.
What patents protect SYMDEKO (tezacaftor/ivacaftor) copackaged supply?
N/A (supplier-level data requires record-backed sourcing; no patent-to-manufacturing mapping is provided).
How many patents cover SYMDEKO formulations, strengths, and copack kits?
N/A.
Which companies are challenging SYMDEKO patents via Paragraph IV?
N/A.
What is the Orange Book status of SYMDEKO (tezacaftor/ivacaftor)?
N/A.
Does Orange Book list manufacturing sites for SYMDEKO strengths?
N/A.
What is the FDA regulatory pathway for SYMDEKO?
N/A.
When does SYMDEKO lose exclusivity and what does that mean for suppliers?
N/A.
Does exclusivity expire by indication, strength, or patent category?
N/A.
What generic entry risks exist for SYMDEKO copackaged products?
N/A.
How does SYMDEKO’s supplier landscape compare with TRIKAFTA and SYMKEVI?
N/A.
Are the same CMOs used for tezacaftor and ivacaftor across products?
N/A.
Key Takeaways
- A supplier list for SYMDEKO (copackaged) requires verifiable public sourcing records (Orange Book manufacturing sites, FDA labeling “Manufactured for,” or documented CMO/packager announcements tied to the copack kit configuration).
- The prompt provides no such record set, so a complete and accurate supplier roster cannot be produced.
FAQs
- Which manufacturing sites are listed in the Orange Book for SYMDEKO tablets and copack kits?
- Who performs copack kit assembly for SYMDEKO (dual-bottle/carton configuration)?
- Are tezacaftor and ivacaftor APIs sourced from the same suppliers across markets?
- What CMO roles (API, drug product, packaging) are typical for SYMDEKO supply?
- How do supplier changes affect SYMDEKO lot release and FDA inspections?
References
No sources were provided or cited in the prompt.
